| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4250866 | Seminars in Nuclear Medicine | 2015 | 8 Pages |
The use of 18F-sodium fluoride (18F-NaF) with PET/CT is increasing. This resurgence of an old tracer has been fueled by several factors including superior diagnostic performance over standard 99mTc-based bone scintigraphy, growth in the availability of PET/CT imaging systems, increase in the number of regional commercial distribution centers for PET radiotracers, the recent concerns about potential recurring shortages with 99mTc-based radiotracers, and the recent decision by the Centers for Medicare and Medicaid Services to reimburse for 18F-NaF PET/CT for evaluation of patients with known or suspected bone metastases through the National Oncologic PET Registry. The major goal of this article is to review the current evidence on the diagnostic utility of 18F-NaF in the imaging assessment of the bone and joint in a variety of clinical conditions.
